Quantcast

Latest Soft tissue sarcoma Stories

2009-05-26 07:47:27

Rhabdomyosarcoma (RMS) is an aggressive muscle cancer that mostly affects children. The most common forms of RMS are embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS). Although ARMS is less common than ERMS, it is associated with a much higher rate of mortality. A therapy tailored to the ARMS form of RMS is therefore badly needed. A team of researchers, at the Hospital for Sick Children, Toronto, and Monash Institute of Medical Research, Australia, has now provided hope...

2009-05-18 12:17:00

SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial...

2009-05-12 06:30:00

CALGARY, May 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) is pleased to announce today that it has successfully completed patient enrolment in its multi-centre Phase 2 clinical trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung. A total of 52 patients have been enrolled in the trial. "We are extremely pleased to have had the opportunity to participate in this study,"...

2009-03-31 11:01:18

In a genetic engineering breakthrough that could help everyone from bed-ridden patients to elite athletes, a team of American researchers"”including 2007 Nobel Prize winner Mario R. Capecchi"”have created a "switch" that allows mutations or light signals to be turned on in muscle stem cells to monitor muscle regeneration in a living mammal. For humans, this work could lead to a genetic switch, or drug, that allows people to grow new muscle cells to replace those that are damaged,...

2009-03-19 13:51:41

New York researchers identified genetic markers that signal poor outcomes for patients with head and neck cancer. The findings, published in the American Journal of Pathology, could one day lead to a genetic test that could help select or predict successful treatment options for patients with tumors in the mouth, throat or larynx. Surgery, chemotherapy and radiation are the main treatment options but cause serious side effects that can affect quality of life. Scientists at Albert Einstein...

0459640684c93d5355bb41efed52c4811
2008-12-30 12:41:40

Researchers at the Ohio State University Comprehensive Cancer Center have discovered that a molecule implicated in leukemia and lung cancer is also important in muscle repair and in a muscle cancer that strikes mainly children. The study shows that immature muscle cells require the molecule, called miR-29, to become mature, and that the molecule is nearly missing in cells from rhabdomyosarcoma, a cancer caused by the proliferation of immature muscle cells. Cells from human rhabdomyosarcoma...

2008-12-11 06:30:00

CALGARY, Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has exceeded the primary statistical endpoint in its multi-centre Phase 2 clinical trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung. "The proportion of patients on study with significant, durable, clinically meaningful responses is highly encouraging," said Dr. Frank Giles, Director...

2008-11-14 09:00:34

CALGARY, Nov. 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Systemic Administration of REOLYSIN Inhibits Growth of Human Sarcoma Xenografts Alone and in Combination with Cisplatin and Radiation" is scheduled to be presented today at the 14th Annual Meeting of the Connective Tissue Oncology Society (CTOS). The meeting is being...

2008-11-05 09:00:34

SALT LAKE CITY, Nov. 5, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) today announced that an article titled "Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose?" was published in The Oncologist (2008;13:175-186) by Peter Hohenberger and Wojciech M. Wysocki. The article reviewed different cancer treatment regimens for treating soft tissue sarcoma (a cancer that occurs in the connective tissues such as muscle), including...

2008-10-16 12:00:05

Ziopharm Oncology, a biopharmaceutical company, has announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion regarding the company's application for orphan medicinal product designation for palifosfamide in the treatment of soft tissue sarcoma. Palifosfamide, the active moiety of ifosfamide (IFOS), is a bi-functional alkylator that causes irreparable inter-strand DNA cross-linking, resulting in cell death. Palifosfamide is equal to...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related